TransCode Therapeutics Analyst Ratings
TransCode Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/24/2023 | 786.26% | HC Wainwright & Co. | → $3 | Reiterates | Buy → Buy |
| 08/15/2023 | 3445.05% | HC Wainwright & Co. | → $12 | Reiterates | Buy → Buy |
| 11/15/2022 | 1672.53% | HC Wainwright & Co. | $10 → $6 | Maintains | Buy |
| 06/07/2022 | 2854.21% | HC Wainwright & Co. | → $10 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 2023 年 10 月 24 日 | 786.26% | HC Wainwright & Co. | → 3 美元 | 重申 | 購買 → 購買 |
| 08/15/2023 | 3445.05% | HC Wainwright & Co. | → 12 美元 | 重申 | 購買 → 購買 |
| 11/15/2022 | 1672.53% | HC Wainwright & Co. | 10 美元 → 6 美元 | 維護 | 買 |
| 2022 年 7 月 6 日 | 2854.21% | HC Wainwright & Co. | → 10 美元 | 啓動覆蓋範圍開啓 | → 購買 |
What is the target price for TransCode Therapeutics (RNAZ)?
TransCode Therapeutics (RNAZ) 的目標價格是多少？
The latest price target for TransCode Therapeutics (NASDAQ: RNAZ) was reported by HC Wainwright & Co. on October 24, 2023. The analyst firm set a price target for $3.00 expecting RNAZ to rise to within 12 months (a possible 786.26% upside). 3 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 於2023年10月24日公佈了TransCode Therapeutics（納斯達克股票代碼：RNAZ）的最新目標股價。該分析公司將目標股價定爲3.00美元，預計RNAZ將在12個月內上漲至786.26％（可能上漲786.26％）。去年有3家分析公司公佈了評級。
What is the most recent analyst rating for TransCode Therapeutics (RNAZ)?
分析師對 TransCode Therapeutics（RNAZ）的最新評級是多少？
The latest analyst rating for TransCode Therapeutics (NASDAQ: RNAZ) was provided by HC Wainwright & Co., and TransCode Therapeutics reiterated their buy rating.
TransCode Therapeutics（納斯達克股票代碼：RNAZ）的最新分析師評級由HC Wainwright & Co. 提供，TransCode Therapeutics重申了他們的買入評級。
When is the next analyst rating going to be posted or updated for TransCode Therapeutics (RNAZ)?
TransCode Therapeutics（RNAZ）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of TransCode Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for TransCode Therapeutics was filed on October 24, 2023 so you should expect the next rating to be made available sometime around October 24, 2024.
分析師在進行了廣泛的研究後得出了股票評級，包括閱讀公開財務報表、與TransCode Therapeutics的高管和客戶交談以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應獲得4個評級。TransCode Therapeutics的最後一次評級是在2023年10月24日提交的，因此你應該預計下一個評級將在2024年10月24日左右公佈。
Is the Analyst Rating TransCode Therapeutics (RNAZ) correct?
分析師對 TransCode Therapeutics (RNAZ) 的評級正確嗎？
While ratings are subjective and will change, the latest TransCode Therapeutics (RNAZ) rating was a reiterated with a price target of $0.00 to $3.00. The current price TransCode Therapeutics (RNAZ) is trading at is $0.34, which is within the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但重申了最新的TransCode Therapeutics（RNAZ）評級，目標股價爲0.00美元至3.00美元。TransCode Therapeutics（RNAZ）目前的交易價格爲0.34美元，在分析師的預測區間內。
譯文內容由第三人軟體翻譯。